Evonik Industries (XTRA:EVK) drew investor interest after committing over CAD 150 million to a new lipid-based drug product facility in Vancouver, along with news of interim leadership changes following CEO Christian Kullmann’s unplanned surgery.
Against this backdrop, Evonik Industries’ share price has gained 7.13% over the past 30 days and 11.78% over 90 days, with a year to date share price return of 41.17% and a 1-year total shareholder return of 21.20%. This indicates momentum that investors appear to be linking to both the Vancouver expansion and leadership continuity.
Spot other chemicals and healthcare suppliers with similar momentum by scanning our hand picked 613 high quality undiscovered gems alongside Evonik Industries.After such a strong run in Evonik Industries following the Vancouver announcement and interim CEO news, the practical question now is whether to accept today’s price or wait for a pullback. The valuation numbers give some context.
Most Popular Narrative: 3% Overvalued
Evonik Industries closed at €18.79 against a most followed narrative fair value of €18.28. That gap is small, so the underlying earnings story matters.
Ramp-up of new production capacities, especially the alkoxides plant in Singapore and the RNA/lipids plant in Slovakia, positions the company to capture incremental volume opportunities tied to sustainable materials and biopharmaceutical applications, supporting medium-term revenue growth.
Read the complete narrative. Read the complete narrative.
Want to see what is backing that fair value for Evonik Industries? The narrative leans on steady top line expansion, higher margins, and a future earnings multiple that assumes the shift toward higher value chemistry continues to hold.
Result: Fair Value of €18.28 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, investors in Evonik Industries still need to weigh weaker demand in key end markets, as well as continued exposure to lower margin commodity chemicals that could pressure the current narrative.
Find out about the key risks to this Evonik Industries narrative.
Another View On Evonik Industries Using Cash Flows
The analyst narrative around Evonik Industries frames the stock as slightly overvalued against an €18.28 fair value. A different lens gives a very different picture. The SWS DCF model estimates the value of future cash flows at €70.39 per share, which points to a large gap versus the current €18.79 price.
This kind of disconnect can reflect how sensitive cash flow models are to long term growth and discount rate assumptions. It also raises a simple question for you as an investor: Is the market being too cautious about Evonik Industries, or is the model being too optimistic about the future cash generation?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Evonik Industries for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 262 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Mixed signals on Evonik Industries so far. If the headlines have caught your attention, take a closer look at the detailed breakdown of 2 key rewards and 3 important warning signs
Looking for more investment ideas beyond Evonik Industries?
If Evonik Industries has sharpened your interest, do not stop here. Broader research with clear filters can help you spot opportunities you might otherwise miss.
- Target dependable income streams by reviewing companies in the 416 dividend fortresses that could suit a long term, income focused approach.
- Reduce potential downside by scanning the 308 resilient stocks with low risk scores so you can focus on businesses with more resilient profiles.
- Hunt for potential future standouts by searching the 212 elite penny stocks with strong financials before they appear on everyone else’s radar.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com